ArticleViruses2019
Amentoflavone Inhibits HSV-1 and ACV-Resistant Strain Infection by Suppressing Viral Early Infection.
Article in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 72 citations in OpenAlex.
- Dimerized Power: The Antimicrobial and Antiviral Promise of Biflavonoids.Biomolecules · 2025Review
- Inhibitory Effect of Amentoflavone on the Virulence of MRSA by Targeting ClpP.Journal of cellular and molecular medicine · 2025Article
- Quercetin inhibits herpes simplex virus 1 replication in corneal epithelium and suppresses keratitis progression.Virologica Sinica · 2025Article
- Inhibition of mitophagy via the EIF2S1-ATF4-PRKN pathway contributes to viral encephalitis.Journal of advanced research · 2025Article
- The multi-pathway treatment of flavonoids as natural compounds in neurological diseases: achievements, limitations, and prospects.Frontiers in neuroscience · 2025Review
- Antiviral Effect of Amentoflavone Against Influenza Viruses.International journal of molecular sciences · 2024Article
- Colloidal Aggregation Confounds Cell-Based Covid-19 Antiviral Screens.Journal of medicinal chemistry · 2024Article
- Anti-HSV-1 agents: an update.Frontiers in pharmacology · 2024Review
- Flavonoids with Anti-Herpes Simplex Virus Properties: Deciphering Their Mechanisms in Disrupting the Viral Life Cycle.Viruses · 2023Review
- Colloidal aggregation confounds cell-based Covid-19 antiviral screens.bioRxiv : the preprint server for biology · 2023Article
- Amentoflavone derivatives significantly act towards the main protease (3CLMolecular diversity · 2023Article
- LIM Kinases, LIMK1 and LIMK2, Are Crucial Node Actors of the Cell Fate: Molecular to Pathological Features.Cells · 2023Review
- A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV.Cureus · 2023Review
- First study onVeterinary world · 2023Article
- In vitro testing and computational analysis of specific phytochemicals with antiviral activities considering their possible applications against COVID-19.South African journal of botany : official journal of the South African Association of Botanists = Suid-Afrikaanse tydskrif vir plantkunde : amptelike tydskrif van die Suid-Afrikaanse Genootskap van Plantkundiges · 2022Article
- Plant Metabolites as SARS-CoV-2 Inhibitors Candidates: In Silico and In Vitro Studies.Pharmaceuticals (Basel, Switzerland) · 2022Article
- The Main Protease of SARS-CoV-2 as a Target for Phytochemicals against Coronavirus.Plants (Basel, Switzerland) · 2022Review
- Antiviral Activities of Officinaloside C against Herpes Simplex Virus-1.Molecules (Basel, Switzerland) · 2022Article
- Biflavonoids: Important Contributions to the Health Benefits of Ginkgo (Plants (Basel, Switzerland) · 2022Review
- Flavonoids Target Human Herpesviruses That Infect the Nervous System: Mechanisms of Action and Therapeutic Insights.Viruses · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection of Herpes simplex virus 1 (HSV-1) induces severe clinical disorders, such as herpes simplex encephalitis and keratitis. Acyclovir (ACV) is the current therapeutic drug against viral infection and ACV-resistant strains have gradually emerged, leading to the requirement for novel antiviral agents. In this study, we exhibited the antiviral activity of amentoflavone, a naturally occurring biflavonoid, toward HSV-1 and ACV-resistant strains. Amentoflavone significantly inhibited infection of HSV-1 (F strain), as well as several ACV-resistant strains including HSV-1/106, HSV-1/153 and HSV-1/Blue at high concentrations. Time-of-drug-addition assay further revealed that amentoflavone mainly impaired HSV-1 early infection. More detailed study demonstrated that amentoflavone affected cofilin-mediated F-actin reorganization and reduced the intracellular transportation of HSV-1 from the cell membrane to the nucleus. In addition, amentoflavone substantially decreased transcription of viral immediate early genes. Collectively, amentoflavone showed strong antiviral activity against HSV-1 and ACV-resistant strains, and amentoflavone could be a promising therapeutic candidate for HSV-1 pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.